High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial.

doi:10.1164/rccm.202311-2004OC

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial.

American journal of respiratory and critical care medicine - 1 Aug 2024

Gausi Kamunkhwala, Ignatius Elisa H, De Jager Veronique, Upton Caryn, Kim Soyeon, McKhann Ashley, Moran Laura, Wiesner Lubbe, von Groote-Bidlingmaier Florian, Marzinek Philip, Vanker Naadira, Yvetot Joseph, Pierre Samuel, Rosenkranz Susan L, Swindells Susan, Diacon Andreas H, Nuermberger Eric L, Denti Paolo, Dooley Kelly E

Abstract excerpt

Rationale: Observational studies suggest that high-dose isoniazid may be efficacious in treating multidrug-resistant tuberculosis. However, its activity against Mycobacterium tuberculosis (M.tb) with katG mutations (which typically confer high-level resistance) is not established. Objectives: To characterize the early bactericidal activity (EBA) of high-dose isoniazid in patients with tuberculosis caused by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bacterial Proteins

Share to Catalase

Share to Dose-Response Relationship, Drug

Share to Isoniazid

Share to Microbial Sensitivity Tests

Share to Mycobacterium tuberculosis

Share to Tuberculosis, Multidrug-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 38564365
DOI: 10.1164/rccm.202311-2004OC
PMCID: PMC11348975

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial.PMID 38564365Read ↗

Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.Semantic proximity Read ↗

Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.Semantic proximity Read ↗

Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.Semantic proximity Read ↗

Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis.Semantic proximity Read ↗

Pharmacogenomics and mutation informatics: correlation of NAT2 mutations and isoniazid acetylation rate.Semantic proximity Read ↗

A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.Semantic proximity Read ↗

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.Semantic proximity Read ↗

Parametric population pharmacokinetics of isoniazid: a systematic review.Semantic proximity Read ↗

Population pharmacokinetics of isoniazid in adult Indian tuberculosis patients: Evaluation of NAT2 polymorphisms.Semantic proximity Read ↗

Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study.Semantic proximity Read ↗

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.Semantic proximity Read ↗

Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the DrugSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.